Natalizumab Tysabri®
The SHIKARI® Natalizumab portfolio combines quantitative free-drug measurement with qualitative and quantitative anti-natalizumab antibody assays for method-controlled research.
Why Natalizumab is relevant to biological-drug monitoring research
Natalizumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Natalizumab is a humanised monoclonal antibody against the α4 subunit of integrins, reducing leukocyte adhesion and migration across vascular endothelium. Source ↗
Approved Indications
In the EU, natalizumab is authorised as disease-modifying monotherapy for highly active relapsing-remitting multiple sclerosis in defined patients. EMA source ↗
IV Peak Exposure Reference
Regulatory-development pharmacokinetic data after a 300 mg intravenous dose provide a concentration reference:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Three verified Natalizumab research assays
Ligand-binding ELISA for quantitative analysis of free natalizumab in human serum or plasma.
Quantitative ELISA for anti-natalizumab antibodies in human serum or plasma, with assay-specific confirmation.
Qualitative ELISA for positive or negative assessment of anti-natalizumab antibodies according to assay-specific cut-off interpretation.
Verified Specifications at a Glance
| Kit | REF | Mode | Analyte | Sample | Volume | Time | Analytical output | Tests | Shelf life | Storage | Shipping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIKARI® Q-NAT | NAT-FD-TYS | Quantitative | Free natalizumab | Human serum / plasma | 10 µL | 70 min | LOD 10 ng/mL; LOQ 30 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATNAT | NAT-QNS-TYS | Quantitative | Anti-natalizumab antibodies | Human serum / plasma | 5 µL | 140 min | LOD 1.87 ng/mL; LOQ 3.125 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATNAT | NAT-QLS-TYS | Qualitative | Anti-natalizumab antibodies | Human serum / plasma | 20 µL | 140 min | Positive / negative | 96 | 1 year | 2–8°C | 10–30°C |
Analytical specifications are summarised from the current controlled IFUs and exact official product records. Standard curves are official illustrative product images and must not be used for sample quantification. Follow the link on each assay card for the corresponding product record on matriksbiotek.com.
Match the assay to the research question
Publications Using SHIKARI® Natalizumab Kits 1
All journal publications below are drawn from the Matrix Biotek Publications library and are shown newest first. Records are included when the publication database identifies the biological drug and SHIKARI® product use.
Planning a Natalizumab research study?
Matrix Biotek can help identify the appropriate Natalizumab assay and prepare regional quotation and delivery information.